PMC:7074424 / 10927-11395 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"233","span":{"begin":290,"end":293},"obj":"Gene"},{"id":"244","span":{"begin":46,"end":49},"obj":"Species"},{"id":"245","span":{"begin":106,"end":114},"obj":"Species"},{"id":"246","span":{"begin":171,"end":179},"obj":"Species"},{"id":"247","span":{"begin":204,"end":212},"obj":"Species"},{"id":"248","span":{"begin":343,"end":351},"obj":"Species"},{"id":"249","span":{"begin":404,"end":412},"obj":"Species"}],"attributes":[{"id":"A233","pred":"tao:has_database_id","subj":"233","obj":"Gene:4283"},{"id":"A244","pred":"tao:has_database_id","subj":"244","obj":"Tax:11118"},{"id":"A245","pred":"tao:has_database_id","subj":"245","obj":"Tax:694009"},{"id":"A246","pred":"tao:has_database_id","subj":"246","obj":"Tax:694009"},{"id":"A247","pred":"tao:has_database_id","subj":"247","obj":"Tax:694009"},{"id":"A248","pred":"tao:has_database_id","subj":"248","obj":"Tax:694009"},{"id":"A249","pred":"tao:has_database_id","subj":"249","obj":"Tax:694009"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"oV with an inhibitor 3X5 240 µM [27]\n4OVZ CoV PLPro complexed with inhibitor P85 490 nM [31]\n3MJ5 SARS-CoV PLPro complexed with inhibitor GRM 320 nM [32]\n2FE8 SARS-CoV PLPro - - [33]\n1UK4 SARS-CoV 3CLPro and its interactions with an inhibitor Substrate analog hexapeptidyl CMK inhibitor IC50 ca. 2 mM [34]\n1UJ1, 1UK3, 1UK2 SARS-CoV M-pro, apo-enzyme at different pH - - [34]\n3VB6 SARS-CoV 3CLPro in complex with C6Z C6Z 39 µM [35]\n3VB5 SARS"}

{"project":"2_test","denotations":[{"id":"32201449-25614110-47217028","span":{"begin":36,"end":38},"obj":"25614110"},{"id":"32201449-24568342-47217029","span":{"begin":96,"end":98},"obj":"24568342"},{"id":"32201449-20527968-47217030","span":{"begin":161,"end":163},"obj":"20527968"},{"id":"32201449-14585926-47217031","span":{"begin":321,"end":323},"obj":"14585926"},{"id":"32201449-14585926-47217032","span":{"begin":394,"end":396},"obj":"14585926"},{"id":"32201449-23202846-47217033","span":{"begin":454,"end":456},"obj":"23202846"},{"id":"T20408","span":{"begin":36,"end":38},"obj":"25614110"},{"id":"T70949","span":{"begin":96,"end":98},"obj":"24568342"},{"id":"T63691","span":{"begin":161,"end":163},"obj":"20527968"},{"id":"T19390","span":{"begin":321,"end":323},"obj":"14585926"},{"id":"T64773","span":{"begin":394,"end":396},"obj":"14585926"},{"id":"T48432","span":{"begin":454,"end":456},"obj":"23202846"}],"text":"oV with an inhibitor 3X5 240 µM [27]\n4OVZ CoV PLPro complexed with inhibitor P85 490 nM [31]\n3MJ5 SARS-CoV PLPro complexed with inhibitor GRM 320 nM [32]\n2FE8 SARS-CoV PLPro - - [33]\n1UK4 SARS-CoV 3CLPro and its interactions with an inhibitor Substrate analog hexapeptidyl CMK inhibitor IC50 ca. 2 mM [34]\n1UJ1, 1UK3, 1UK2 SARS-CoV M-pro, apo-enzyme at different pH - - [34]\n3VB6 SARS-CoV 3CLPro in complex with C6Z C6Z 39 µM [35]\n3VB5 SARS"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T41","span":{"begin":106,"end":114},"obj":"Disease"},{"id":"T42","span":{"begin":106,"end":110},"obj":"Disease"},{"id":"T43","span":{"begin":171,"end":179},"obj":"Disease"},{"id":"T44","span":{"begin":171,"end":175},"obj":"Disease"},{"id":"T45","span":{"begin":204,"end":212},"obj":"Disease"},{"id":"T46","span":{"begin":204,"end":208},"obj":"Disease"},{"id":"T47","span":{"begin":343,"end":351},"obj":"Disease"},{"id":"T48","span":{"begin":343,"end":347},"obj":"Disease"},{"id":"T49","span":{"begin":404,"end":412},"obj":"Disease"},{"id":"T50","span":{"begin":404,"end":408},"obj":"Disease"},{"id":"T52","span":{"begin":464,"end":468},"obj":"Disease"}],"attributes":[{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A48","pred":"mondo_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"oV with an inhibitor 3X5 240 µM [27]\n4OVZ CoV PLPro complexed with inhibitor P85 490 nM [31]\n3MJ5 SARS-CoV PLPro complexed with inhibitor GRM 320 nM [32]\n2FE8 SARS-CoV PLPro - - [33]\n1UK4 SARS-CoV 3CLPro and its interactions with an inhibitor Substrate analog hexapeptidyl CMK inhibitor IC50 ca. 2 mM [34]\n1UJ1, 1UK3, 1UK2 SARS-CoV M-pro, apo-enzyme at different pH - - [34]\n3VB6 SARS-CoV 3CLPro in complex with C6Z C6Z 39 µM [35]\n3VB5 SARS"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T98","span":{"begin":36,"end":38},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T99","span":{"begin":147,"end":150},"obj":"http://purl.obolibrary.org/obo/CLO_0003564"},{"id":"T100","span":{"begin":290,"end":293},"obj":"http://purl.obolibrary.org/obo/CLO_0002526"},{"id":"T101","span":{"begin":321,"end":323},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T102","span":{"begin":394,"end":396},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T103","span":{"begin":454,"end":456},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"}],"text":"oV with an inhibitor 3X5 240 µM [27]\n4OVZ CoV PLPro complexed with inhibitor P85 490 nM [31]\n3MJ5 SARS-CoV PLPro complexed with inhibitor GRM 320 nM [32]\n2FE8 SARS-CoV PLPro - - [33]\n1UK4 SARS-CoV 3CLPro and its interactions with an inhibitor Substrate analog hexapeptidyl CMK inhibitor IC50 ca. 2 mM [34]\n1UJ1, 1UK3, 1UK2 SARS-CoV M-pro, apo-enzyme at different pH - - [34]\n3VB6 SARS-CoV 3CLPro in complex with C6Z C6Z 39 µM [35]\n3VB5 SARS"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T88","span":{"begin":11,"end":20},"obj":"Chemical"},{"id":"T89","span":{"begin":71,"end":80},"obj":"Chemical"},{"id":"T90","span":{"begin":136,"end":145},"obj":"Chemical"},{"id":"T91","span":{"begin":249,"end":258},"obj":"Chemical"},{"id":"T92","span":{"begin":294,"end":303},"obj":"Chemical"}],"attributes":[{"id":"A88","pred":"chebi_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A89","pred":"chebi_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A90","pred":"chebi_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A91","pred":"chebi_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A92","pred":"chebi_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"oV with an inhibitor 3X5 240 µM [27]\n4OVZ CoV PLPro complexed with inhibitor P85 490 nM [31]\n3MJ5 SARS-CoV PLPro complexed with inhibitor GRM 320 nM [32]\n2FE8 SARS-CoV PLPro - - [33]\n1UK4 SARS-CoV 3CLPro and its interactions with an inhibitor Substrate analog hexapeptidyl CMK inhibitor IC50 ca. 2 mM [34]\n1UJ1, 1UK3, 1UK2 SARS-CoV M-pro, apo-enzyme at different pH - - [34]\n3VB6 SARS-CoV 3CLPro in complex with C6Z C6Z 39 µM [35]\n3VB5 SARS"}

{"project":"LitCovid-sentences","denotations":[{"id":"T67","span":{"begin":40,"end":99},"obj":"Sentence"},{"id":"T68","span":{"begin":100,"end":164},"obj":"Sentence"},{"id":"T69","span":{"begin":165,"end":197},"obj":"Sentence"},{"id":"T70","span":{"begin":198,"end":313},"obj":"Sentence"},{"id":"T71","span":{"begin":314,"end":324},"obj":"Sentence"},{"id":"T72","span":{"begin":325,"end":397},"obj":"Sentence"},{"id":"T73","span":{"begin":398,"end":457},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"oV with an inhibitor 3X5 240 µM [27]\n4OVZ CoV PLPro complexed with inhibitor P85 490 nM [31]\n3MJ5 SARS-CoV PLPro complexed with inhibitor GRM 320 nM [32]\n2FE8 SARS-CoV PLPro - - [33]\n1UK4 SARS-CoV 3CLPro and its interactions with an inhibitor Substrate analog hexapeptidyl CMK inhibitor IC50 ca. 2 mM [34]\n1UJ1, 1UK3, 1UK2 SARS-CoV M-pro, apo-enzyme at different pH - - [34]\n3VB6 SARS-CoV 3CLPro in complex with C6Z C6Z 39 µM [35]\n3VB5 SARS"}